The data underlying the results is included in the supporting materials

Introduction {#sec006}
============

The NHS is facing unsustainable pressures as evidenced in recent attendance figures for Emergency departments (ED) and General Practice (GP) consultations in England. \[[@pone.0230343.ref001],[@pone.0230343.ref002]\] A recent report claimed that 5% of ED consultations and 13% of GP consultations are for low acuity conditions, generally termed minor ailments. \[[@pone.0230343.ref003]\] These medical complaints are considered common, uncomplicated or self-limiting which do not require medical (i.e. doctor) intervention, but are appropriately managed through symptom relief and self-care. \[[@pone.0230343.ref004]\]

A recent systematic review investigated minor ailment services in UK and Canada and found structural differences in service design and delivery. \[[@pone.0230343.ref005]\] However, Paudyal *et al*. have reported that minor ailment services have the potential to reduce GP minor ailment workload, produce positive health outcomes and are associated with positive stakeholder views. \[[@pone.0230343.ref006]\]

In the UK, the Department of Health has advocated the management of low acuity conditions in community pharmacy, thus freeing up physicians' time and resources in ED departments and GP surgeries. \[[@pone.0230343.ref003]\] However, although some studies have suggested that pharmacy minor ailment services may be valuable, \[[@pone.0230343.ref007]\] the services have faced controversy and fluctuating investment in resource and consideration. A recent study found that the main barriers to the embedding and sustainability of these services were the historical poor service design, development and implementation, and lack of recorded evidence. \[[@pone.0230343.ref008]\] On a more general level, the 2016 independent review of community pharmacy clinical services found the main barriers to successful clinical service provision were:

-   poor integration of community pharmacy within the wider NHS, accompanied with a lack of digital inoperability;

-   poor recognition by the public and other healthcare professionals as an appropriate healthcare option;

-   overly complex and disjointed commissioning and regulatory systems, and

-   ineffective use of the diverse skill mix within the workforce. \[[@pone.0230343.ref009]\]

In order to address the specific challenge of integrating community pharmacy into the wider NHS, NHS England established the Pharmacy Integration Fund (PhIF) to support the development of new pharmacy services, working practices and digital platforms to meet the public's expectations for a modern NHS pharmacy service.

One service piloted by the PhIF was the Digital Minor Illness Referral Service (DMIRS), which tested the technical integration and clinical governance framework for referral from the telemedical helpline, NHS 111, to community pharmacy for people needing immediate help with minor ailments. \[[@pone.0230343.ref010]\] A list of 72 specific minor illnesses, such as cough, colds and sore throat, were identified *via* stakeholder consensus workshops to be safely and appropriately managed in community pharmacy. \[[@pone.0230343.ref010]\] The workshops were underpinned by participatory service design, with representatives from the key major stakeholder groups in the NHS 111 system, as depicted in [Fig 1](#pone.0230343.g001){ref-type="fig"}. \[[@pone.0230343.ref010]\]

![The NHS 111 system highlighting the key stakeholders involved in the management of a patient call.](pone.0230343.g001){#pone.0230343.g001}

Phase 1 of this pilot involved DMIRS becoming operational across the North East region of England in December 2017.

This study aims to investigate the feasibility and delivery of the DMIRS pilot in the North East of England. Service activity data will be investigated to explore the nature and burden of patient referrals to community pharmacy. The perspectives of service designers, commissioners, providers and users will be captured and scrutinised to assess elements of service implementation and delivery. It is anticipated that these findings are crucial to provide information to service designers, implementers and commissioners about the feasibility in wider adoption of the service but also provide insight on the aspects of the system and process that might require onward optimisation, monitoring and evaluation towards better understanding the outcomes and success of the service.

Methods {#sec007}
=======

Study design {#sec008}
------------

A mixed methods convergent design was used, combining the service activity data of DMIRS between Jan 2018 --Dec 2018, and qualitative interviews with stakeholders to evaluate the service. Data collection across these two approaches occurred in parallel and analysis for integration commenced after data was collected. Findings from this combination of methodologies are anticipated to provide service designers and commissioners with evidence of potential service impact but also information on future service development and optimisation. Ethical approval was obtained from the Faculty of Medical Sciences Ethical Committee, Newcastle University (1612/7270/2018 and 1612/7209/2018).

Setting {#sec009}
-------

Phase 1 of the DMIRS pilot was commissioned by NHS England Cumbria and North East as a local enhanced service. The service became operational in December 2017 and by June 2018, DMIRS was available in 388 out of 643 pharmacies (who specifically signed up to provide the service) across the North East (NE) region, covering ten clinical commissioning groups (CCGs) across Northumberland, Tyne and Wear, Durham, Darlington and Tees.

Description of the intervention (DMIRS) {#sec010}
---------------------------------------

The DMIRS involves the referral of patients from NHS 111, to community pharmacy for specific minor illnesses deemed appropriate for management by a pharmacist.

NHS 111 call handlers, who are not healthcare trained, identify patients presenting with minor illnesses, using a structured questioning approach. The computer decision software prompts the call handlers to refer patients to the closest registered community pharmacy to the patient's home postcode signed up to provide the service from their Directory of Services.

After referral, patients attend the community pharmacy for a private consultation with the pharmacist, structured to investigate the presenting complaint, provide appropriate advice and/or offer an over-the-counter medicinal product to purchase.

The Template for Intervention Description and Replication (TIDieR) checklist, \[[@pone.0230343.ref011]\] included in the Supporting information ([S1 Table](#pone.0230343.s001){ref-type="supplementary-material"}), was used to ensure adequate reporting of the service.

Service activity data {#sec011}
---------------------

The period of evaluation is Jan 2018 to Dec 2018. No patient identifiable information was included in the service activity data (this has been made available in Supporting information ([S1 File](#pone.0230343.s002){ref-type="supplementary-material"})). From NHS 111 the extracted routinely recorded service activity data included:

-   Patient demographics (age and gender);

-   The shortened postcode of the patient, including their 2015 Index of Multiple Deprivation (IMD) decile, the postcodes of their GP practice and the community pharmacy to which the patient was referred;

From the community pharmacy routine service activity data the following was extracted for purposes of evaluation:

-   The time of the NHS 111 call and the time the referral was actioned;

-   The minor condition for which the patient called NHS 111;

-   The outcomes of the referrals and reasons for rejections where this was provided;

-   The completion outcomes of the community pharmacist consultation.

IMD 2015 deciles were used to map the deprivation of those using the service. The IMD is an overall measure of multiple deprivation experienced by people living in an area, and comprises 37 separate indicators organised across seven domains of deprivation (income, employment, health and disability, education, skills and training, crime, barriers to housing and services and living environment) which are combined, using appropriate weights. \[[@pone.0230343.ref012]\]

Quantitative data relating to the service activity was analysed using descriptive and. Text entered into free text boxes was coded manually to enable inclusion in the analysis.

Stakeholder investigation {#sec012}
-------------------------

Semi-structured telephone interviews were used for data collection in the attempt to engage with as many stakeholders as possible causing the minimal inconvenience.

Sampling {#sec013}
--------

Purposive sampling with the help of the DMIRS project manager \[AY\], was used to identify the key project team members.

Convenience sampling was used to recruit the other participants. NHS 111 call handlers were invited to take part in the study via an email from the Team leader (a project team member). They were asked to contact the independent researcher \[HN\] directly about participation. Community pharmacists, who had indicated interest in the evaluation at a DMIRS engagement event, were approached. These stakeholders were considered as key informants, \[[@pone.0230343.ref013]\] capable of providing key insight into the implementation and delivery of the service. Patients attending the community pharmacy for their DMIRS referral were asked to provide consent and their preferred mode of contact to partake in future service evaluation.

Data collection from all stakeholders continued until inductive thematic saturation was reached whereby no further new codes or themes could be identified during analysis rather than aiming for completeness of existing theoretical categories (theoretical saturation), which would have been a strategy aligning more strictly with a grounded theory approach. \[[@pone.0230343.ref014]\]

Recruitment {#sec014}
-----------

All stakeholders were contacted by their preferred method. Where emails were not provided in the first instance, these were requested to send the participant information sheets and consent forms electronically for consideration and completion prior to any involvement in the study.

Data collection and analysis {#sec015}
----------------------------

The Consolidated Framework for Advancing Implementation Research \[[@pone.0230343.ref015]\] was utilised in developing the key informant interview topic guides. The recommended structure for these topic guides were informed by recommendations from O'Haire *et al*. \[[@pone.0230343.ref013]\]

For the patient topic guide, questions were mapped to stages of the referral process. Topic guides were tested for face validity with a sample of each of the stakeholder groups and are available in the Supporting information (S3 Topic Guides).

Telephone interviews were audio-recorded with consent, transcribed verbatim and analysed using thematic analysis. An inductive approach to data analysis was adopted, where themes were generated empirically from the data with no imposition of *a priori* presumptions. This constructivist orientation is dependent upon the mutual interpretation of the interviewer and interviewee as the interview unfolds, where the final analysis is assumed to reach a balance between the interacting interpretations. \[[@pone.0230343.ref016]\] To minimise researcher bias in this process, two researchers \[HN, ZN\] independently analysed the transcripts, meeting intermittently to discuss impressions and initial codes and categories. Where discrepancies in findings and abstractions occurred, a third member of the research team \[LL\] was consulted for consensus. The thick description derived from the interviews, aimed to improve the transferability of the findings and conclusions thereby offering a form of external validity as recommended by Lincoln and Guba. \[[@pone.0230343.ref017]\] Further incorporating researchers within the team not involved in the research process, allowed the process and product of the study to be scrutinised providing an external audit to increase dependability. \[[@pone.0230343.ref017]\]

Results {#sec016}
=======

Referral data {#sec017}
-------------

A total of 13,246 patient calls to NHS 111 were referred to community pharmacy *via* DMIRS during the evaluative period. This equates to approximately 1,103 monthly referrals to the 388 community pharmacies across the pilot region, equating to around 2.8 referrals to each pharmacy over the period. The rate of referrals fluctuated throughout the year, but, generally, the numbers increased during the winter months (Oct-Feb), with an observable dip during the months that followed (Feb-Sept), as shown in [Fig 2](#pone.0230343.g002){ref-type="fig"}.

![The number of NHS 111 calls that were referred to community pharmacy over the course of 2018.](pone.0230343.g002){#pone.0230343.g002}

The calls were made across a 24 hour period, with the lowest volume occurring in the early hours after midnight 02:00--05:00 (n = 196, 1.5%), with an increase between 05:00--08:00 (n = 679, 5.1%), with the largest volumes occurring between 08:00--12:00 (n = 4,849, 36.7%), then numbers slowly declined again throughout the day. The increase in referrals for younger patients (0--9 years old) started earlier in the day in comparison to other age groups; another peak in the afternoon to early night time, 15:00--20:00 was also observed for this patient group.

The largest proportion of referrals, 25.1% (n = 3314) were for patients aged between 0--9 years old, followed by those aged between 20--29 years, representing 21% (n = 2793) of the volume. Decreasing numbers of patients called through to NHS 111 and were referred to pharmacy with increasing age, to the lowest population of 90--100 year olds, representing just 0.2% (n = 20) of the referrals. More referrals were made for females than males (n = 7483, 56.5%, *vs*. n = 5763, 43.5%).

Across the listed conditions, there was some similarity in the minor conditions referred to community pharmacy for both males and females, with acute pain (n = 1144, 8.6%) and cough (n = 887, 6.7%) being the most common ([Table 1](#pone.0230343.t001){ref-type="table"}).

10.1371/journal.pone.0230343.t001

###### Common conditions suffered by males and females that were referred to community pharmacy.

![](pone.0230343.t001){#pone.0230343.t001g}

  Condition           Female (n, % of total females)   Male (n, % of total males)   Total (n, %)
  ------------------- -------------------------------- ---------------------------- --------------
  Acute pain          635 (8.5)                        509 (8.8)                    1144 (8.6)
  Allergic rash       280 (3.7)                        184 (3.2)                    464 (3.5)
  Colds               169 (2.3)                        136 (2.4)                    305 (2.3)
  Cough               462 (6.2)                        425 (7.4)                    887 (6.7)
  Diarrhoea           142 (1.9)                        122 (2.1)                    264 (2.0)
  Headache/Migraine   166 (2.2)                        124 (2.2)                    290 (2.2)
  High temperature    180 (2.4)                        175 (3.0)                    355 (2.7)
  Infection           172 (2.3)                        184 (3.2)                    356 (2.7)
  Rash                163 (2.2)                        122 (2.1)                    285 (2.2)
  Sore throat         284 (3.8)                        157 (2.7)                    441 (3.3)
  Strains/sprains     143 (1.9)                        125 (2.2)                    268 (2.0)
  **5059 (38.2)**                                                                   

The age profiles for patients presenting with common minor conditions are shown in [Fig 3](#pone.0230343.g003){ref-type="fig"}. Allergic rash, cough and high temperature were most commonly observed in younger patients (0--9 years old), while people presenting with acute pain was most common in the 20--38 years age range.

![The age profiles for patients who were referred to the community pharmacy according to the presenting condition.](pone.0230343.g003){#pone.0230343.g003}

Of the 13,246 calls, 6233 (47.1%) were completed, 2786 (21.0%) escalated, and 4227 (31.9%) rejected ([Table 2](#pone.0230343.t002){ref-type="table"}).

10.1371/journal.pone.0230343.t002

###### The outcomes of the NHS 111 calls that were referred to community pharmacy.

![](pone.0230343.t002){#pone.0230343.t002g}

  Outcome                                                        Additional notes                                                        Number of patients (%)
  -------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------
  Completion                                                     Advice given with safety netting[\*](#t002fn001){ref-type="table-fn"}   3442 (55.2)
  Advice given and sale/supply of a medicine                     2776 (44.5)                                                             
  Appropriate treatment at pharmacy, e.g. wound dressing         2 (-)                                                                   
  Unknown                                                        13 (-)                                                                  
  Escalation                                                     Pharmacy called 999                                                     8 (-)
  Referral to GP                                                 1171 (42.3)                                                             
  Referral to NHS 111                                            1046 (37.7)                                                             
  Referral to secondary care                                     352 (12.7)                                                              
  Referral to specialist, e.g. dentist                           28 (1.0)                                                                
  Referral unspecified                                           181 (6.5)                                                               
  Rejection                                                      Did not attend                                                          355 (8.4)
  Inappropriate referral, escalation without contact             128 (3.0)                                                               
  Patient has appointment with another healthcare professional   739 (17.5)                                                              
  Patient recovering/no longer required help                     389 (9.2)                                                               
  Other                                                          33 (0.1)                                                                
  Patient seen by another healthcare professional                441 (10.4)                                                              
  Patient uncontactable                                          1894 (44.9)                                                             
  Unknown                                                        248 (5.9)                                                               

\*safety netting involved providing patients with information about the development of signs and symptoms that would require they seek further medical attention (otherwise termed 'signposting').

For the most common conditions, the level of completion of the NHS 111 referral to community pharmacy was good (\> 60%) ([Table 3](#pone.0230343.t003){ref-type="table"}), with infections being the exception (33.7% completion).

10.1371/journal.pone.0230343.t003

###### The outcomes of the most prevalent conditions that were referred onto community pharmacy.

![](pone.0230343.t003){#pone.0230343.t003g}

  Condition           Outcome (n, %)   Total (n)              
  ------------------- ---------------- ------------ --------- ------
  Acute pain          792 (69.3)       343 (30.0)   9 (0.8)   1144
  Allergic rash       387 (83.4)       72 (15.5)    5 (1.0)   464
  Colds               254 (83.3)       46 (15.1)    5 (1.6)   305
  Cough               656 (74.0)       224 (25.3)   7 (0.8)   887
  Diarrhoea           222 (84.0)       41 (15.5)    1 (0.4)   264
  Headache/Migraine   178 (61.4)       112 (38.6)   0 (0.0)   290
  High temperature    245 (69.0)       108 (30.4)   2 (0.6)   355
  Infection           120 (33.7)       235 (66.0)   1 (0.3)   356
  Rash                174 (61.1)       109 (38.2)   2 (0.7)   285
  Sore throat         313 (70.9)       124 (28.1)   4 (0.9)   441
  Strains/sprains     217 (80.9)       51 (19.0)    1 (0.4)   268

For other less common conditions, completion rates were lower (\< 50%), with many falling below 30%, as illustrated in [Table 4](#pone.0230343.t004){ref-type="table"}.

10.1371/journal.pone.0230343.t004

###### The conditions that demonstrated higher rates of escalation after being referred onto community pharmacy.

![](pone.0230343.t004){#pone.0230343.t004g}

  Condition                       Outcome (n, %)   Total (n)              
  ------------------------------- ---------------- ------------ --------- -----
  Chest infection                 13 (32.5)        27 (67.5)    0 (0.0)   40
  Ear condition (other)           14 (35.0)        25 (62.5)    1 (2.5)   40
  Gout                            19 (44.2)        23 (53.4)    1 (2.3)   43
  Gynaecological query            11 (42.3)        15 (57.7)    0 (0.0)   26
  Impetigo                        29 (34.1)        54 (63.5)    2 (2.4)   85
  Infection (unspecified cause)   120 (33.7)       235 (66.0)   1 (0.3)   356
  Shingles                        47 (46.5)        54 (53.5)    0 (0.0)   101
  Tonsillitis                     8 (27.6)         20 (69.0)    1 (3.4)   29
  Urinary tract infection         17 (30.1)        38 (69.1)    0 (0.0)   55

Only 24.2% (n = 1,506) of patients with a completed referral received a sale or supply of an over-the-counter medication. The most commonly supplied medications included: antihistamines (n = 152, 10.7%), non-opioid analgesics (n = 195, 12.9%), non-steroidal anti-inflammatories (n = 208, 13.8), and sympathomimetics, cough suppressants, demulcents and mucolytics (n = 141, 9.4%).

People living in the most deprived areas of England where more commonly referred into the service than people living in more affluent areas. Indeed, around 25% of patients referred to a community pharmacy were from the IMD decile 10 (the most deprived 10% of Lower Level super output (LSOAs) areas nationally), shown in [Fig 4](#pone.0230343.g004){ref-type="fig"}. While community pharmacies located in the most deprived areas where responsible for receiving the most patient referrals, as shown in [Fig 5](#pone.0230343.g005){ref-type="fig"}.

![The number of community pharmacy NHS 111 referrals according to area-level deprivation of the patient (1 is highest deprivation, 10 is the lowest).](pone.0230343.g004){#pone.0230343.g004}

![The number of community pharmacy NHS 111 referrals according to area-level deprivation of the community pharmacy (1 is highest deprivation, 10 is the lowest).](pone.0230343.g005){#pone.0230343.g005}

Stakeholder investigation {#sec018}
-------------------------

A mix of stakeholders were interviewed between Dec 2018 and May 2019, including: NHS 111 call handlers *\[CH\]* (n = 14); Project team members *\[TM\]* (n = 6); Community Pharmacists *\[CP\]* (n = 12) and Patients and the Public *\[PP\]* (n = 30). Average length of interviews was 21.5 mins ± 7.1 with a range 12.3--32.4 mins.

The findings from the stakeholder interviews are presented below with illustrative quotations.

During the analysis, themes emerged from the CH, CP and TM interviewee transcripts that demonstrated how DMIRS had caused aspects of change in thinking and/or process of working, e.g. the intervention had brought about change in the behaviours of NHS 111 call handlers, and insinuated that DMIRS will bring about change in patients seeking care and advice for low acuity conditions. As such, the themes have been mapped to the components of the behaviour change wheel as described by Michie *et al*. \[[@pone.0230343.ref018]\] The specific aspects of the wheel have been used to frame the emerging themes to facilitate coherency of discourse below and has been visually summarised in [Fig 6](#pone.0230343.g006){ref-type="fig"}.

![The behaviour change wheel and the aspects that were referred to, and the emerging themes, through the qualitative interviews with stakeholders.](pone.0230343.g006){#pone.0230343.g006}

NHS 111 team members {#sec019}
--------------------

-   Psychological Capability and Reflective Motivation of NHS 111 call handlers enhanced by Education, Enablement & Training

All call handlers described and demonstrated commitment to the intended objectives for DMIRS as shifting the burden of low acuity conditions from urgent and emergency care (UEC) to community pharmacy. They were very positive about the progress of the service and described a strengthened belief in community pharmacy as the appropriate healthcare professional to refer those patients. Most had some previous awareness of the potential roles and responsibilities of community pharmacists. To the participants, the dedication of the project manager in delivering a tailored presentation to them in their workplace and coaching them was immeasurably valuable.

> *'When we had that presentation by the pharmacist*, *he was great*. *He explained what pharmacists could do...he then spent time*, *one-on-one with us to help us understand pharmacists better and answer our questions*.*' \[CH3\]*

Gaining this knowledge provided the interviewees with confidence in advising calling patients to attend community pharmacy for their complaints. Call handlers described how their negotiating ability was strengthened by their improved awareness, enabling them to reassure and educate the patients about the abilities of community pharmacists.

> *'I had a lot more to say to the patient about what a pharmacist could do for them*. *It helps...we have training in negotiating*, *but we don't have a script to read to convince people...The visit from the pharmacist built my confidence to offer community pharmacy to the patient*.*'\[CH11\]*

-   Physical Capability of NHS 111 call handlers facilitated by the Environmental Restructuring

DMIRS was reported as non-disruptive to the normal daily working practices of the call handlers. The hurdle of recommending it to patients and managing reactions was the most noticeable adjustment to practice. The patient response was largely of acceptance and perceived compliance. Even the occasional declines were something the call handlers were used to.

> *'It's part of what we see...patients declining what we offer them*. *They know they want to see a doctor and just won't accept anything else...I think the rate of that happening with this* \[DMIRS\] *is similar to what we usually see*.'*\[CH4\]*

Similarly, call handlers articulated that the current referral back to NHS 111 *via* an escalation process from community pharmacy, was not noticeably significant and appeared justified, as patients were often found to have more concerning symptoms when they consulted a pharmacist than they originally disclosed on the phone.

> *'There hasn't been a lot that has come back to us from what I can remember*. *But the ones that have*, *have been those that seemed more well when they spoke to us*. *So it makes sense they were referred back*' *\[CH7\]*

Call handlers believed this service was adding value to patients and the wider NHS system and advocated for continued investment. There was an expressed appreciation and anticipation that the current offering of DMIRS could lead to overall patient and public education about self-care and the possibility of the community pharmacy being the first port-of-call without having to call through to NHS 111.

There were recommendations of wider community pharmacy engagement, more use of the pharmacists' skills with respect to management of minor infections and prescribing of antibiotics specifically.

> *'It would be great if we could refer more patients into it* \[DMIRS\]. *Then there would be more awareness and acceptance...So if pharmacists could provide antibiotics or help with more conditions like infections*, *things would be easier all round*.'*\[CH2\]*
>
> *'It's really about educating the public about what pharmacy can do*, *so that's who they go to next time...and tell other people*.'*\[CH13\]*

### Project team members {#sec020}

-   Physical Opportunity & Capability of patients and pharmacists facilitated by Environmental restructuring

For the team members, DMIRS offered means to educate patients and the public, improving their psychological capability and perceived opportunity of accessing care and advice from a community pharmacy for low acuity conditions. They all emphasised how DMIRS was an opportunity to evidence the contribution of community pharmacy within the wider NHS system, especially in shifting patient burden from other areas of UEC.

> *'It really is an opportunity for pharmacists to demonstrate what they can do for the NHS...relieve the significant burden in out of hours services...with the evidence*, *it can really pave the way for more clinical services going to pharmacy*.'*\[TM4\]*

There was expressed anticipation that DMIRS would improve wider confidence and awareness in community pharmacy, enabling investment into further service optimisation, and development and better integration into the NHS.

-   Reflective Motivation of service designers, managers and providers through Education and Enablement

The multi-disciplinary approach taken within the planning workshops that informed the development of DMIRS was appreciated. These activities were crucial to raise awareness and understanding of the interfaces and complexity between NHS 111, UEC, community pharmacy and the patients and public. DMIRS was built upon dialogue and knowledge exchange across these interfaces, and the perceived result was a cohesive service, providing safe and effective care.

> *'The way it was done from the outset...the planning*, *the conversations*, *it really made a difference*. *The groundwork done has meant we all have a better understanding of the system*. *We work better and can see how to move this forward*. *We haven't done this thorough work for other services before and it shows in the dramatic results this service has achieved*.*'\[TM2\]*

It was recognised that engagement of service managers was integral to successful implementation and accelerated adoption of DMIRS. Giving the service providers direct access to the managers through engagement events and one-on-one interactions, provided the opportunity to educate them about the wider service system and other actors within the provision. This increase in awareness of the component parts, individual contributions and potential outcomes, resonated strongly with project team members and NHS 111 call members. Linked to this was a perceived increase in the reflective motivation and psychological capability of service providers to engage with service provision.

> *'The enthusiasm from the project lead to come in and talk about this with passion...taking time to dedicate to engagement*, *has really been a significant driver for this service*. *It has really accelerated change*.*'\[TM6\]*

-   Moving past barriers: Motivation of pharmacists and of patients improved through Education, Modelling and Enablement

Project team members agreed that raising public awareness about the service would create a proactive message about accessing care from the community pharmacy for low acuity conditions. Also further communication and tailored training for service providers, especially community pharmacists, was suggested. For them, increasing reflective motivation was seen as the focus of this promotion, to encourage behaviour change in order to increase engagement and drive for service provision. DMIRS, was deemed vital to not only sustainability and effectiveness of this service, but to improving the integration into the NHS and provision of clinical services.

> *'Community pharmacists really need to understand the bigger picture of where this service fits*. *They need to appreciate how much of an opportunity DMIRS presents*. *I think that will drive motivation and engagement...but communicating to such a large group is difficult*. *We need more engagement events...better attended...more marketing*.'*\[TM1\]*

Community pharmacists {#sec021}
---------------------

-   DMIRS benefits from existing Motivation and Capability of pharmacists

Community pharmacists agreed that DMIRS was a good idea and should involve pharmacy. For them, DMIRS was a valuable way to ease pressures on GPs and hospitals. There was a shared sense of a natural fit into the normal workflow of the pharmacy without creating additional burden on pharmacist time, although some felt the associated paperwork was lengthy. It was also seen as an opportunity to make their knowledge and skills known.

> *'\[Pharmacists are\] accessible...no appointment needed so should be the first port of call...DMIRS is the beginning of the future*' *\[CP4\]*

Community pharmacies felt prepared to include more clinical services into their practices. Availability of private consultation rooms, with computers for the referral software was an element of this readiness. Pharmacists found patients quite receptive of the service. The patient response was overall positive, except where the patient required onward referral. This was seen as a standard practice for any patient whose condition might require more specialist attention.

> *'I think they* \[patients\] *are happy*, *they seem happy*. *Except...those ones who don't get what they need in the pharmacy and need to go on somewhere else*.' *\[CP10\]*

-   Improving pharmacists Capability with Education, Environmental restructuring and Enablement

Some pharmacists were concerned about time the consultations took. They felt unable to participate as fully as they had hoped to, but were supportive of DMIRS and wished to be involved as staffing issues were resolved. Further training and upskilling of pharmacists was also identified as an issue. There was a need to be better equipped for managing referrals, and providing the confidence and competence aligning to the increasingly clinical direction of the profession.

> *'...we can't do chest examinations*, *and look into people's throats or ears*. *So some tailored training would be great to get us up to speed*.' *\[CP14\]*
>
> *'A lot of what is needed is a good*, *thorough consultation*. *We don't need to examine everything*, *but we do need to do a clinical consultation...in most cases this is enough and some of us* \[community pharmacists\] *will have the confidence to do this*, *but I can imagine there a load of pharmacists who might not*.'*\[CP10\]*

Some participants felt that a few of the referrals into pharmacy were inappropriate and required escalation to a doctor. Others perceived this as part of a normal care pathway, where further clinical triage in the pharmacy, after a non-clinical telephone conversation, may lead to an onward referral. Some pharmacists acknowledged that the patients' answers to NHS 111 call handlers may not fully reflect the nature of their complaint, resulting in the subsequent escalation from the community pharmacist.

> *'Patients may answer questions differently to NHS 111*, *and we see them* \[in the community pharmacy\] *it's obvious they should not be here...*.*but we don't know those questions and answers' \[CP5\]*

Pharmacists mentioned other referral services (e.g. the NHS Urgent Medicines Supply Advanced Service) and felt that it would be beneficial for consistency of care to have an integrated approach to delivery and funding. Moving forward, community pharmacists think DMIRS is viable, deliverable and facilitates delivery of other clinical services.

> *'Another step towards educating the public...it enables us to provide other services as well...and people*, *once they have been through this service*, *will come again to see us*.*'\[CP6\]*

-   Improving community pharmacy's Opportunity to be involved through better Marketing

There were concerns regarding the slow uptake of the service by the public, and comments about the need to promote DMIRS to manage patient expectations better. Some pharmacists thought the NHS 111 call handlers could educate patients about the role of the pharmacist. Better understanding was thought to help with patients' expectations and reduce inappropriate referrals to community pharmacy.

> *'When patients are referred they don't understand what they are going to receive in the pharmacy and don't like having to pay for products*' *\[CP9\]*

Patients and the public {#sec022}
-----------------------

Overall the patients were positive about the service. Only two patients reported poor experiences, both had called with concerns about a young child. They had presented to the referred community pharmacy and were advised to attend the walk-in centre. The patient representatives expressed dissatisfaction and felt they should have originally been referred to the more urgent clinical setting.

> *'The pharmacist just said they had to refer us to the walk in centre because they couldn't do anything*. *It was just a waste of time*. *We should have got sent there in the first place*.*'\[PP5\]*

Most of the patients described their experience of community pharmacy positively. For many, their health concern had been addressed solely with advice or with the addition of an over-the-counter remedy. Patients' previous experience with a community pharmacy prepared them to some degree of the capability and knowledge of the pharmacist.

> *'I use my pharmacy all the time for my medication*, *and they are always really good*. *So I was happy when the lady on the phone said try the pharmacy first*.*'\[PP11\]*

Even if patients' conditions had not been resolved or improved by attending the community pharmacy, they were complementary. Pharmacist were seen as professional and considerate, providing useful reassurance and advice.

> *'I showed him the burn on my hand*. *He gave it a good clean and gave me a dressing but said I would need someone to look at it because of my old skin*. *He didn't say that*, *but he said my skin would take longer to heal*, *especially because of the medication I was on*. *When I went to the doctor*, *he said the pharmacist was right and it's good he told me to come because I needed to take some antibiotics for a while after that to stop an infection*.*'\[PP3\]*

Those with no previous experience with a community pharmacy, described a sense of surprise and appreciation for their role and the service provided.

> *'I didn't know pharmacists knew like how to check you like a doctor or nurse*. *They did my blood pressure as well*, *so yea I was happy with that*.'*\[PP8\]*

Participants acknowledged the burden on the wider NHS and felt that community pharmacy could provide some relief for patients. For them, community pharmacy provided a good 'middle ground', when the condition needed some attention but not urgent care before a potentially long-awaited GP appointment.

> *'I knew I needed someone to have a look but I knew that it wasn't urgent*, *so I like that the pharmacist could have a look and give advice because it just wasn't like overly urgent or dangerous*.'*\[PP21\]*

There was expression that the service and advice that can be provided in a community pharmacy was reassuring, convenient and of clinical value. A few patients felt that if pharmacists had the capacity to do more, like prescribe, the offering would be much more significant.

> *'It would be better if a pharmacist could do more*. *Like she told me I needed antibiotics*, *but it would have been great if she could have just prescribed some there and then*.*'\[PP17\]*

Some patients stated that the experience of attending a community pharmacy *via* DMIRS meant that they will attend a community pharmacy first upon experiencing a minor condition in future rather than contacting NHS 111.

> *'Even though I had to go on and see my doctor cos the tablets didn't help very much*, *I would go back to the pharmacy for something minor*. *They were just really efficient and listened to me*.*'\[PP28\]*

Discussion {#sec023}
==========

In this study, the quantitative service activity data of the regional minor illness pilot, DMIRS, (service research) has been presented and supplemented with contextual information about the feasibility in the implementation, adoption, delivery and outcomes of that service (implementation research).

The use of this service appears to mirror use of NHS 111 in general, where calls are more likely to be received from females and for younger age groups. \[[@pone.0230343.ref019]\] Anderson *et al*. also reported a significant volume of calls to NHS 111 were for patients up to the age of 9 years old, but also patients aged over 80 years were highly represented. \[[@pone.0230343.ref020]\] It is also clear that the pilot has demonstrated the feasibility of shifting patient burden from urgent and emergency care to community pharmacy for a range of low acuity conditions. This corresponds with a previous study which demonstrated that 27.8% of NHS 111 call handler cases referred to Accident and Emergency reviewed by a panel of GPs during Sep-Dec 2014, would have been advised to self-care or other management services (including referral to community pharmacy). \[[@pone.0230343.ref021]\]

The analysis of the patients being referred to pharmacy, offers service managers and providers the opportunity to optimise resource and training for the future. For example, awareness around the patient groups (demographics) and conditions can inform the educational training packages required for community pharmacists to improve effective service delivery. For stakeholders monitoring the key performance indicators and patient safety; the rates of completion, escalation and rejection are important towards refining the service specification and mitigating risk. Those conditions which currently have high escalation rates, should be considered in service optimisation, but also demonstrate a need for training and capacity in community pharmacy. Many of those conditions with higher escalation rates are infections, which could, after appropriate clinical examination, warrant the need for a prescribed course of antibiotics. Community pharmacists and NHS 111 call handlers have also recognised the potential increased value of DMIRS if more pharmacists were able to safely and appropriately prescribe or supply (e.g. under a patient group direction) antibiotics.

Further valuable deductions possible with this data set relate to the most used, or appropriate medicines for the most prevalent low acuity conditions. Until now a formulary for minor ailments services has not been empirically informed or evidenced, instead included medicines were subject to regional variation and unstandardized decision-making of local Clinical Commissioning Groups. The data from DMIRS offers commissioners and service designers substantial evidence to inform formularies if commissioned minor ailment services were to continue.

The qualitative component of this investigation has provided some insight to potentially explain how a regional pilot gained such traction for wider adoption and, relatively quickly, informed changes to contractual requirements and national practice. Some of the data included in this study was included in an interim pilot evaluation, undertaken by the PhIF evaluation team in NHS England. Evidence from this investigation went on to inform the five-year framework for GP services, published in January 2019, by NHS England. NHS England stated in this document that DMIRS had demonstrated that many patients, who would have otherwise been advised to attend general practice, could have been successfully managed in a community pharmacy setting. \[[@pone.0230343.ref021]\]

The momentum of interest in the value of DMIRS has been further manifested in the new Community Pharmacy Contractual Framework announced in July 2019. \[[@pone.0230343.ref022]\] A new 'Community Pharmacy Consultation Service' (CPCS) has been proposed to replace the local pilots of DMIRS, as well the current NHS urgent Medicine Supply Advanced Service (NUMSAS). The new CPCS was proposed to launch in October 2019 as an integrated part of the contractual framework. \[[@pone.0230343.ref022]\] This means that pharmacists signing up to provide this service would be remunerated as a standard for their provision.

Stakeholders from the NHS 111 system in our study have described behaviour change in their practice that was facilitated through implementation processes influencing various aspects of the policy categories and intervention functions outlined in the behavioural change wheel. \[[@pone.0230343.ref019]\] The implementation process appears to have impacted these aspects within the different settings that make up the NHS 111 system, e.g. NHS 111 call handler setting, community pharmacy setting. This multi-faceted approach to implementation could be considered a reasonable explanation for the wider adoption and impact of the pilot, since the process of implementation undertook a more holistic, systems approach in setting up and managing service delivery. This strategy also attains a level of success across three concepts of sustainability as outlined by Moullin *et al*.: \[[@pone.0230343.ref023]\]

-   Firstly, the implementation process has fortified the routinisation of pharmacy minor illness service delivery; reinforced the institutionalisation through evolving supportive conditions, and ensured the maintenance of benefits through adopting technological systems enabling service data collection to evidence service outcomes.

-   The implementation process has considered the context and environment rather than just focusing on the specific setting of service delivery, i.e. community pharmacy. The process has influenced factors to ensure the environment is conducive to successful service delivery.

-   There was local buy-in and support across the stakeholders involved in the service system as demonstrated in the initial consensus workshops utilised to frame the service. \[[@pone.0230343.ref010]\] Progressing forward, the national political support and revised fiscal structure of the new pharmacy contract further supports longer term implementation and sustainability. \[[@pone.0230343.ref022]\]

From the community pharmacists' data around unpreparedness, there is potentially more investment required into the training and persuasion to increase motivation and capability to provide DMIRS. In tackling these areas, the fidelity and quality of service provision will be improved, thereby further enhancing impact, outcomes and sustainability of DMIRS. The evidence from successful implementation and service delivery will support the development and implementation of further clinical service provision from community pharmacy. There has been an indication that the next model of care to layer on top of DMIRS, is GP referral to community pharmacy for minor illness. So, with each iterative development, community pharmacy has the opportunity to evidence their contribution to healthcare, optimise skills and knowledge and become a more integrated player within the NHS system, thereby addressing the key barriers that were identified by the NHS England independent review of community pharmacy clinical services. \[[@pone.0230343.ref009]\]

The patients and public generally reported positive experience through accessing services *via* DMIRS. Porteous *et al*. also reported that patients preferred to practice self-care for minor conditions and access a community pharmacy for advice with a key motivating factor being reduced waiting times and incurred costs. \[[@pone.0230343.ref024]\] Todd *et al*. demonstrate that the majority of the population can access a community pharmacy within a 20 minute walk, where no appointment is required. Also, patients in areas of greatest deprivation, which contribute a greater volume of DMIRS referrals, have even greater access to community pharmacy. \[[@pone.0230343.ref025]\]

The overall long-term aim of DMIRS, and indeed a proposed GP referral to community pharmacy, is to educate and empower patients and the public to promote self-care of minor conditions. Through remodelling the NHS care pathways, highlighting through explicit referral and marketing of community pharmacy, it is anticipated that health-seeking behaviours can be changed to reduce the unsustainable pressures on GP and urgent and emergency care for conditions that patients could manage themselves with minimal clinical input. In order to assess for this as a consequence of DMIRS (and the subsequent CPCS), a longitudinal assessment of patient knowledge and health-seeking practices around low acuity conditions would be pragmatic. It would be anticipated that call volumes for such presenting complaints would also decrease over time, as patients instead self-present at community pharmacy, with no prompting from contact with an NHS service.

Limitations {#sec024}
-----------

Our study is limited by the nature of the routine service activity data made available as part of a service evaluation. It would have been ideal to verify that those patients referred to pharmacy did not re-enter the system by seeking medical care from their GP practice or accessing UEC again. However, tracking patients fell outside the remit and ethical permissions of this work. Similarly, we have explained the exploratory approach we have adopted here to investigate the feasibility of shifting patient burden and scrutinising the implementation process and delivery. We also propose that an explanatory study is now conducted to investigate the referral rate of patients by NHS 111 call handlers (or fidelity of service provision) to assess the burden of patients still be managed in UEC, and explore the reasons why, e.g. negotiating skills of NHS 111 call handlers. Similarly, completion rate of community pharmacists warrant further study to address any barriers or concerns downstream in the service system that risk successful normalisation and sustainability.

The qualitative data, by its very nature, does not suggest generalisability, however, we have, through adopting inductive thematic saturation, provided some detailed insight into the mechanics of the service implementation and delivery. We have not presented feedback and perspectives from doctors, however, it has been reported in an internal NHS England report, that DMIRS has saved substantial GP appointment time across the pilot period. Also, doctors, specifically those with roles in UEC, were involved in the participatory design of the service as described in our previous study. \[[@pone.0230343.ref010]\] However, as this service is rolled out nationally and with plans to design and implement a GP to community pharmacy referral pathway for low acuity conditions, engaging with and investigating perspectives of doctors would be informative.

Conclusions {#sec025}
===========

This study is timely to report upon the service activity data of a regional pilot that rapidly informed healthcare policy and practice in relation to managing the burden of low acuity conditions presenting in the urgent and emergency care setting. The qualitative data provides in-depth, contextual information to highlight the processual underpinnings of the design, implementation and delivery of the service which contributed to its wider adoption. DMIRS has demonstrated to be a success story for community pharmacy as it serves as a step towards improved integration within the wider NHS and provides a proof of concept for the delivery of clinical services with the ability to gather self-certifying evidence of safe, valuable and effective practice.

Supporting information {#sec026}
======================

###### The Template for Intervention Description and Replication (TIDIER) checklist for the digital minor illness referral service.

(DOCX)

###### 

Click here for additional data file.

###### The service activity data for the digital minor illness referral service.

(XLSM)

###### 

Click here for additional data file.

###### Stakeholder semi-structured interview topic guides.

(DOCX)

###### 

Click here for additional data file.
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Reviewer \#1: The paper focuses on an important issue, addressing a contemporary population health need. The authors used a large dataset to evaluate the effectiveness of a digital referral system towards shifting the burden of urgent and emergency care services by referring patients calling NHS 111 with low acuity conditions to community pharmacists. To improve the readability and application of the findings of this paper, the authors need to make some major revision of the current version.

The Authors need to identify who their target audience is and tailor the presentation of the results to meet their context and needs. The results of the qualitative strand while important is too long. This will be a challenge for easy assimilation by readers who have less time to read a long paper. The authors should consider alternative forms such as visual representing of the results in a figure to accommodate such readers.

There is a need for more discussion of the system to help readers understand its functionality. Authors need to consider unintended consequences of the system especially in their discussion of the findings. How is this accounted for in the development of the system? Does the system consider patient history such as comorbidities, for instance, in the decision on community pharmacist referral? What is the possible harm from the high proportion of referrals among patients aged 0-9 years considering the inability of this age group to extensively self-report their symptoms (themselves or through a third party such as caregivers) given the reliance of the system on symptoms described by patients?

The quantitative strand of the paper was too descriptive and do not present strong empirical evidence to inform policy decisions and the translation of this intervention in other settings. The dataset holds more potentials for an extensive evaluation of the system. The authors need to apply more robust statistical models in understanding the factors associated with the performance of the system. The data on patients' demography, for instance, could be used to model the behaviour of rejecting referrals for community pharmacist consultations. As a process evaluation paper aiming to optimise the potentials of the DMIRS system, one will expect a detailed investigation to understand why 1/3 of those referred rejected.
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The Authors reported adopting a mixed-methods design in their paper. Although the results of analyses of qualitative and quantitative data were presented, there was a lack of integration of both methods expected in a mixed-methods design. It is unclear how the design of the interview relates to the analysis and results of the service activity data. Both strands do not seem to complement each other. For instance, the interview result in lines 258-264 on the negotiating abilities of the call handlers could inform statistical investigation towards the level of rejections. Rejection as an outcome of the referral process could be patterned alongside call handler characteristics such as negotiating ability and understanding this pattern is important in optimising acceptance of the referral system.

The qualitative interviews present important insights into the implementation of the intervention and can be a standalone study. I recommend the authors consider splitting the manuscript into two papers, focusing the current paper on the qualitative study exploring the experiences and perspectives of stakeholders in the implementation of the DMIRS system in North East of England. Alternatively, to maintain a mixed-methods design, the statistical analysis should be improved by conducting more robust investigations, and both strands should be well integrated.
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Line 94: is this an exploratory or explanatory mixed methods design? It is unclear how the design of the interview relates to the service activity data. Both strands do not seem to complement each other.

Line 105: add some examples of these specific minor illnesses. It is helpful to prepare your readers at this point on the conditions considered to be low acuity.

Lines 222-226: I was interested in seeing how this will be interpreted in the discussion section. Are those of lower IMD generally more likely to call NHS 111 for low acuity conditions compared to those of higher IMD? Are those of higher IMD more likely to call NHS 111 for more serious/high acuity conditions. Can these explain the high referral into the service seen in the most deprived areas of England?

Line 231: what informed the decision on the number of interviews to conduct and the proportion of each group (CH, TM, CP) contributing to the stakeholders\' data? This needs to be explained.

Reviewer \#2: Overall, I think this is an interesting evaluation of a unique (and needed) service. (Granted, I am a pharmacist, so I am a bit biased in that area.) The paper is well-written and makes a compelling argument in favor of these types of referrals to community pharmacists for the treatment of minor illnesses. My comments are mainly related to adding additional detail to help readers who are unfamiliar with the UK health care system better understand the referral service developed in this pilot program.

1\. At several points in the paper, a list of low acuity conditions are mentioned, but these are never really defined until the Results. Were these conditioned defined prior to the implementation of this service (e.g., as part of the pilot program development)? Some discussion of what these conditions are and how they were selected might be helpful, especially for those who might be interested in implementing this outside the UK.

2\. Related to the previous point, some Canadian provinces have implemented pharmacist prescribing for minor ailments. It might be helpful to provide some mention of these efforts outside the UK to provide additional context. This would probably be a discussion point.

3\. In the introduction, some of the information struck me as potentially being better suited for the Discussion section. Mainly, the 2nd and 3rd full paragraphs on page 4. Those seem to discuss the status of the DMIRS program after what is being evaluated in the current paper. By presenting these up front, it felt a little out of order to me. You might consider moving these to the end of the paper as a sort of "where is it now" part of the discussion.

4\. It would be helpful to explain who the call handlers were. Were these nurses or somebody else? If not nurses, did they have any health care training? That was a big question in my mind in terms of their ability to make appropriate referrals to the community pharmacist vs. to the GP or ED.

5\. When referrals were made to a community pharmacy, the call handler selected the pharmacy closest to the patient's home address. Was there any consideration of whether or not that was the patient's "usual" pharmacy? Sometimes people use pharmacies that aren't necessarily the closest geographically to their home.

6\. For the participating pharmacies, were these all community pharmacies or only certain ones who were signed up to be part of this pilot service? (My apologies if I missed that in the paper.)

7\. On page 6 under Service activity data, the first paragraph and the data extra description seemed a little redundant. You might consider reworking those to combine them without being repetitive. For example, the first paragraph mentions the what was recorded and then the second part notes the data extracted. These are basically the same elements in that prior paragraph.

8\. Under Sampling (page 7, line 152), patients attending the community pharmacy referral were asked to provide consent for participation in research and evaluation. Strictly speaking, this project is not research, rather it is an evaluation. Is the "research and evaluation" terminology used because the consent was for the DMIRS pilot more generally (and potential follow-up projects)? You might clarify this and update the wording if needed.

9\. In Table 2, the term "safety netting" is used, but it is not defined. This may be a common term for the UK context, but it may not be familiar to those elsewhere.

10\. In the results referring to the level of completion (bottom of page 10, line 209; top of page 11, line 214), a percentage is listed in parentheses. It is unclear if these percentages are what were used for "good" vs. "not good" in terms of completion. Please clarify this.

11\. The supplemental figure for the Michie wheel (page 12, line 243) was not available when I checked the supplemental information. I was only able to access the TIDieR table. I'm not sure if this was a technological issue on my end or if the file wasn't attached.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr Philip Anyanwu

Reviewer \#2: Yes: Spencer E. Harpe

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230343.r002

Author response to Decision Letter 0

5 Feb 2020

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response to editor:

These style changes have been made.

2\. Please address the following:

\- Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section, including the potential bias introduced by the sampling method used and the nature of qualitative data.

Response to editor:

Thank you for highlighting this missing information which has now been included.

\- Please include additional information regarding the semi-structured interview guide used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a guide as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. In addition, please include any details of pre-testing of this guide, including the number of participants and where they were recruited from.

Thank you for your attention to these queries.

Response to editor:

Apologies, we intended to supply the interviews guides but appear not have done so with the original submission. We have made them available in this submission.

3\. Thank you for stating the following in the Financial Disclosure section:

\"HN received funds to undertake evaluative work for the Digital Minor Illness Referral Service from NHS England (Grant number: BH181784). Funders supported the study design, data collection, analysis and decision to publish the work.\"

We note that one or more of the authors are employed by a commercial company: Local Professional Network.

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[HN\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Response to editor

We have included an amended financial and competing interest statement in our cover letter as requested.

4\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response to editor:

We now include the data set as supporting material.

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response to editor:

These changes have been made.

The methods refer to the qualitative analysis as using both a modified grounded theory approach as well as thematic analysis. This is confusing -since no theory was proposed, how is this grounded theory. Referring to the study as thematic analysis seems suitable.

Response to editor:

Thank you for highlighting this discrepancy. We have addressed this by indicating a pragmatic convergent (or concurrent) design to data collection was adopted with an inductive coding strategy leading to thematic analysis. We believe this more accurately describes our data collection and analysis.

Can the authors comment on a further aspect of pharmacists\' opinions - namely that apparently pharmacists were providing referral services without recompense for their time and effort. The pharmacy literature is replete with \"wonderful\" studies of pharmacists giving away their services for free. Such pharmacy programs rarely seem to be scalable or replicable because not all pharmacists are so public minded as to work for free towards the public good.

Response to editor:

I appreciate this perspective, however this pilot led to a change to the national pharmacy contract, so that this service is now subject to remuneration. So we do not present a case where pharmacists are doing this for free, instead this study has provided evidence to demonstrate pharmacists role in minor ailment management (which before now has not been tangible) to substantiate the need to remunerate pharmacists.

A major stakeholder not included in the analysis is that of physicians. Can the authors address this oversight.

Response to editor:

Thank you, yes I see why this could be seen as an oversight, however, doctors (specifically out-of-hours doctors) were involved in the initial design of the service. Their perspectives were taken into account about management and safety of the patients. It would be useful to now interview doctors about their views of a wider roll out of this service which we have recommended for future work.

Reviewer \#1:

The paper focuses on an important issue, addressing a contemporary population health need. The authors used a large dataset to evaluate the effectiveness of a digital referral system towards shifting the burden of urgent and emergency care services by referring patients calling NHS 111 with low acuity conditions to community pharmacists. To improve the readability and application of the findings of this paper, the authors need to make some major revision of the current version.

Response to reviewer:

We thank the reviewer for his thorough considerations and suggestions for the work and hope amendments have made the work more readable and comprehensive.

The Authors need to identify who their target audience is and tailor the presentation of the results to meet their context and needs. The results of the qualitative strand while important is too long. This will be a challenge for easy assimilation by readers who have less time to read a long paper. The authors should consider alternative forms such as visual representing of the results in a figure to accommodate such readers.

Response to reviewer:

We have introduced the aim of the work in the 'study design', where we outline how the study design has been tailored to the interest of service designers, commissioners and potentially policy makers. We concede that the qualitative data, as might be expected, is lengthy, we have developed a visual representation that we hope summarises much of the findings to accommodate reads wanting a more efficient means of understanding the data.

There is a need for more discussion of the system to help readers understand its functionality. Authors need to consider unintended consequences of the system especially in their discussion of the findings. How is this accounted for in the development of the system? Does the system consider patient history such as comorbidities, for instance, in the decision on community pharmacist referral? What is the possible harm from the high proportion of referrals among patients aged 0-9 years considering the inability of this age group to extensively self-report their symptoms (themselves or through a third party such as caregivers) given the reliance of the system on symptoms described by patients?

Response to reviewer:

We have included figure 1, from a previous study, to better represent the NHS 111 system. We appreciate the questions posed by the reviewer as crucial in the service design. These considerations have been addressed in our previous study, were a participatory design approach was utilised to account for pharmacist competence, availability of resources and treatments in the pharmacy and managing potential patient escalation or onward referral.

The quantitative strand of the paper was too descriptive and do not present strong empirical evidence to inform policy decisions and the translation of this intervention in other settings. The dataset holds more potentials for an extensive evaluation of the system. The authors need to apply more robust statistical models in understanding the factors associated with the performance of the system. The data on patients' demography, for instance, could be used to model the behaviour of rejecting referrals for community pharmacist consultations. As a process evaluation paper aiming to optimise the potentials of the DMIRS system, one will expect a detailed investigation to understand why 1/3 of those referred rejected.

Response to reviewer:

These are very valid and useful comments. In reframing our study as a pilot, assessing the feasibility in implementing and delivering this service, we believe the descriptive nature of the quantitative service activity data is appropriate. The service activity data has provided evidence to policy-makers that referral to community pharmacy is a feasible pathway. Our study aim was to assess the feasibility of delivering the service, rather than explaining the service or exploring factors associated with how well it performs. Data not collected by the research team, has allowed the same policy makers to assess that the new service pathway saves GP time, and does not result in duplicated presentation of patients at GP practices and out-of-hours services. Unfortunately, as this data was not part of the routine service activity data, it has not been made accessible to the research team to complement and substantiate the findings in this work.

With the current analysis, it is unclear whether the DMIRS is actually shifting the burden of low acuity conditions from urgent and emergency care. It is possible for those referred and completed to go back to their GP or A&E. The possibility of this happening was reiterated in the interview result (lines 270-272). The authors need to consider this in plans to improve the statistical analysis.

Response to reviewer:

An in-depth process evaluation to understand some of the service activity figures is indeed now warranted, given that the pathway has shown to be feasible. This is outside the scope and the aim of this study and would recommend current service leads and commissioners to monitor and evaluate service performance to understand the service outcomes. This would ensure cycles of quality improvement towards more effective and efficient service delivery. As reiterated previously, service leads are reassured that patients are not re-entering the system. However, given this relies on access to patient-identifiable data to allow trackability, the research team did not have access to this information to assess and therefore report it here.

The Authors reported adopting a mixed-methods design in their paper. Although the results of analyses of qualitative and quantitative data were presented, there was a lack of integration of both methods expected in a mixed-methods design. It is unclear how the design of the interview relates to the analysis and results of the service activity data. Both strands do not seem to complement each other. For instance, the interview result in lines 258-264 on the negotiating abilities of the call handlers could inform statistical investigation towards the level of rejections. Rejection as an outcome of the referral process could be patterned alongside call handler characteristics such as negotiating ability and understanding this pattern is important in optimising acceptance of the referral system.

Response to reviewer:

We appreciate the reviewer's comments about the perceived lack of coherency between the adopted methodologies. We hope that the reframing of the paper around investigating feasibility of the referral pathway addresses this concern. We explain our convergent study design and how integration of findings were undertaken post data collection to scrutinise the feasibility and outcome of the service. In relation to better understanding the presented service activity data, we agree with the reviewer, that an explanatory approach is appropriate and potentially prove very useful. In our exploratory approach, we would contest, that we have identified potential aspects of the system and the process would warrant evaluation going forward, e.g. observational assessment of call handlers as they manage patient calls to assess the correlation between negotiating capabilities and referral uptake rate. We have included this proposition in our recommendations for future work.

The qualitative interviews present important insights into the implementation of the intervention and can be a standalone study. I recommend the authors consider splitting the manuscript into two papers, focusing the current paper on the qualitative study exploring the experiences and perspectives of stakeholders in the implementation of the DMIRS system in North East of England. Alternatively, to maintain a mixed-methods design, the statistical analysis should be improved by conducting more robust investigations, and both strands should be well integrated.

Response to reviewer:

We appreciate this recommendation, but would reflect that such a study would be one with a different set of aims and objectives; a set that looks to investigate in-depth the nuances of service outcomes and effects. This would be a much needed study to follow-on from and be informed by the work we present in this paper.

We believe that coupling the service activity data alongside the qualitative data provides a more informed perspective of feasibility and better highlights aspects of the service that require further scrutiny and evaluation.

Minor comments

Line 51: brief explanation (1 or 2 sentences) of what low acuity conditions mean. This will be useful to the non-clinical audience.

Response to reviewer:

We have added in an explanation so the reader is made aware at the onset of the paper.

Line 94: is this an exploratory or explanatory mixed methods design? It is unclear how the design of the interview relates to the service activity data. Both strands do not seem to complement each other.

Response to reviewer:

We thank the reviewer for highlighting this and have added some text to explain the exploratory approach adopted here.

Line 105: add some examples of these specific minor illnesses. It is helpful to prepare your readers at this point on the conditions considered to be low acuity.

Response to reviewer:

We have added a few examples to raise awareness earlier on reading.

Lines 222-226: I was interested in seeing how this will be interpreted in the discussion section. Are those of lower IMD generally more likely to call NHS 111 for low acuity conditions compared to those of higher IMD? Are those of higher IMD more likely to call NHS 111 for more serious/high acuity conditions. Can these explain the high referral into the service seen in the most deprived areas of England?

Response to reviewer:

Indeed those are very interesting lines of inquiry, however, we only have data for patients referred into DMIRS, so cannot make assumptions of all patients calling NHS 111 for low acuity conditions. This would warrant further investigation.

Line 231: what informed the decision on the number of interviews to conduct and the proportion of each group (CH, TM, CP) contributing to the stakeholders\' data? This needs to be explained.

Response to reviewer:

We have included our approach to continue data collection until inductive thematic saturation had been reached. This guided the number of interviews conducted within each stakeholder group.

Reviewer \#2: Overall, I think this is an interesting evaluation of a unique (and needed) service. (Granted, I am a pharmacist, so I am a bit biased in that area.) The paper is well-written and makes a compelling argument in favor of these types of referrals to community pharmacists for the treatment of minor illnesses. My comments are mainly related to adding additional detail to help readers who are unfamiliar with the UK health care system better understand the referral service developed in this pilot program.

Response to reviewer:

We thank the reviewer for their considerate and thorough review of our work.

1\. At several points in the paper, a list of low acuity conditions are mentioned, but these are never really defined until the Results. Were these conditioned defined prior to the implementation of this service (e.g., as part of the pilot program development)? Some discussion of what these conditions are and how they were selected might be helpful, especially for those who might be interested in implementing this outside the UK.

Response to reviewer:

With thanks, we have provided an explanation of minor conditions and some examples in the introduction so readers are made aware early on in reading the paper.

2\. Related to the previous point, some Canadian provinces have implemented pharmacist prescribing for minor ailments. It might be helpful to provide some mention of these efforts outside the UK to provide additional context. This would probably be a discussion point.

Response to reviewer:

We have made mention that a recent systematic review investigated minor ailment services internationally and found studies published from UK and Canada so readers are made aware of thwe wider provision of these services.

3\. In the introduction, some of the information struck me as potentially being better suited for the Discussion section. Mainly, the 2nd and 3rd full paragraphs on page 4. Those seem to discuss the status of the DMIRS program after what is being evaluated in the current paper. By presenting these up front, it felt a little out of order to me. You might consider moving these to the end of the paper as a sort of "where is it now" part of the discussion.

Response to reviewer:

We appreciate this perspective and have moved this information to the discussion as suggested. We agree that this is more appropriate as data presented in the paper did lead to those specific developments.

4\. It would be helpful to explain who the call handlers were. Were these nurses or somebody else? If not nurses, did they have any health care training? That was a big question in my mind in terms of their ability to make appropriate referrals to the community pharmacist vs. to the GP or ED.

Response to reviewer:

We have verified that call handlers are not health-care trained staff.

5\. When referrals were made to a community pharmacy, the call handler selected the pharmacy closest to the patient's home address. Was there any consideration of whether or not that was the patient's "usual" pharmacy? Sometimes people use pharmacies that aren't necessarily the closest geographically to their home.

Response to reviewer:

Indeed we can agree this is the case. However, other factors were taken into consideration when selecting the pharmacy: opening hours (given that many patients called outside of normal working hours), and sending to only those pharmacies which had signed up to provide the service. This has been clarified in the text.

6\. For the participating pharmacies, were these all community pharmacies or only certain ones who were signed up to be part of this pilot service? (My apologies if I missed that in the paper.)

Response to reviewer:

Apologies, this was missing from the paper and has now been added.

7\. On page 6 under Service activity data, the first paragraph and the data extra description seemed a little redundant. You might consider reworking those to combine them without being repetitive. For example, the first paragraph mentions the what was recorded and then the second part notes the data extracted. These are basically the same elements in that prior paragraph.

Response to reviewer:

Thank you for pointing this out. We have moved repetitious wording as recommended.

8\. Under Sampling (page 7, line 152), patients attending the community pharmacy referral were asked to provide consent for participation in research and evaluation. Strictly speaking, this project is not research, rather it is an evaluation. Is the "research and evaluation" terminology used because the consent was for the DMIRS pilot more generally (and potential follow-up projects)? You might clarify this and update the wording if needed.

Response to reviewer:

Apologies, yes this could be misleading. We have removed the 'research' component as this was indeed considered service evaluation.

9\. In Table 2, the term "safety netting" is used, but it is not defined. This may be a common term for the UK context, but it may not be familiar to those elsewhere.

Response to reviewer:

Yes, this is an oversight on our part and we have now provided some further explanation.

10\. In the results referring to the level of completion (bottom of page 10, line 209; top of page 11, line 214), a percentage is listed in parentheses. It is unclear if these percentages are what were used for "good" vs. "not good" in terms of completion. Please clarify this.

Response to reviewer:

Yes, the percentages in the parentheses were misplaced in the sentence making it confusing; this has been amended.

11\. The supplemental figure for the Michie wheel (page 12, line 243) was not available when I checked the supplemental information. I was only able to access the TIDieR table. I'm not sure if this was a technological issue on my end or if the file wasn't attached.

Response to reviewer:

Apologies, this was missing. We have now incorporated this figure into the manuscript to visually summarise the qualitative data (figure 6).
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**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors have responded to review comments and amended the manuscript accordingly.

A limitation section has been included by the authors to further demonstrate the scope of the investigations conducted.

Reviewer \#2: Thank you for your responses to the comments from the editors and the reviewers. All of my concerns were addressed. I think the paper is stronger and tells a more clear story about this interesting service that was implemented.
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If you choose "no", your identity will remain anonymous but your review may still be made public.
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